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Abstract
Background: With the increasing use of nanomaterials, the need for methods and assays to examine their
immunosafety is becoming urgent, in particular for nanomaterials that are deliberately administered to human
subjects (as in the case of nanomedicines). To obtain reliable results, standardised in vitro immunotoxicological
tests should be used to determine the effects of engineered nanoparticles on human immune responses. However,
before assays can be standardised, it is important that suitable methods are established and validated.
Results: In a collaborative work between European laboratories, existing immunological and toxicological in vitro
assays were tested and compared for their suitability to test effects of nanoparticles on immune responses. The
prototypical nanoparticles used were metal (oxide) particles, either custom-generated by wet synthesis or
commercially available as powders. Several problems and challenges were encountered during assay validation,
ranging from particle agglomeration in biological media and optical interference with assay systems, to chemical
immunotoxicity of solvents and contamination with endotoxin.
Conclusion: The problems that were encountered in the immunological assay systems used in this study, such as
chemical or endotoxin contamination and optical interference caused by the dense material, significantly affected
the data obtained. These problems have to be solved to enable the development of reliable assays for the
assessment of nano-immunosafety.
Background
The potential benefits and the risks associated with the
application of nanomaterials have been widely debated
in recent years. The need to correctly assess nanoparti-
cle (NP) risks in order to protect workers, consumers
and the environment is well accepted in the scientific
and regulatory community [1,2]. Both the human popu-
lation and the environment may be exposed to nanoma-
terials during all stages of the NP life cycle: raw material
production, transport and storage, industrial use,
consumer use, and waste disposal. The consumer use
can vary from products like coated textiles or paints,
where the presence of nano-products is not clearly sta-
ted, to sunscreens, where the NP content is explicitly
labelled. In addition, medical use of NPs for diagnostic
purposes or as drug delivery backbone represents inten-
tional exposure to significant NP doses. Currently, a
variety of methodologies are being discussed and evalu-
ated to perform a complete risk assessment of nanoma-
terials. There are a number of European legislations that
have the objective of implementing laws regarding use
of and exposure to nanomaterials [3,4] including the
REACH programme [5]. However, a lack of information
on exposure levels, in vitro and in vivo NP effects and
* Correspondence: geja.oostingh@sbg.ac.at
1Department of Molecular Biology, University of Salzburg, 5020 Salzburg,
Austria
Full list of author information is available at the end of the article
Oostingh et al. Particle and Fibre Toxicology 2011, 8:8
http://www.particleandfibretoxicology.com/content/8/1/8
© 2011 Oostingh et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
the life cycle of these entities make implementation of
standards extremely difficult.
Even though a wealth of publications addresses the
delicate issue of toxicity of engineered NPs [1,6,7], the
exact events that occur in the interaction between NPs
and the immune system are still largely unknown, even
though nanoparticle-induced alterations of the immune
system can have important effects on human health [8].
Despite a worldwide effort, results are overall contradic-
tory, in particular when (immuno-) toxicity of NPs
in vitro or in vivo is concerned, and no clear-cut infor-
mation can be provided to the policy-makers, the pro-
ducers and workers, and the public at large. Results
obtained in different laboratories can often not be com-
pared because of a lack of disclosure of experimental
details as well as a lack of standardisation of methods
and reagents.
An important aspect is that nanoparticle characterisa-
tion should also be performed at the point of use, since
ageing, storage conditions and contamination can mod-
ify their properties in important ways. Alterations in
particle characteristics can also occur when nanomater-
ials get in contact with the human body or with biologi-
cal entities in the environment. Biological molecules can
modify the nanomaterials and cause dissolution, aggre-
gation or, at the very least, coating. The result can be
anything from free ions or chemicals released from
nanomaterials to micrometer-sized aggregates. Coating,
for example by polysaccharides or proteins, may render
the materials less harmful but can also change their
properties in unexpected ways [9,10]. Furthermore, asso-
ciation with biological molecules such as endotoxins,
can strongly affect the immunological response towards
the particles.
For the analysis of the effects of nanoparticles on the
immune system, the use of in vivo models can help in
identifying possible risks for human health [11]. The
adsorption, distribution, metabolism and excretion
(ADME) of these materials may play a major role in
immunotoxicity and can only be studied in vivo in ani-
mal models [12,13]. However, how well animal models
reflect the real-life situation in humans and how well
the results from these animal models correspond to the
events observed after exposure of human beings to NPs
is still to be determined. The use of in vitro assays with
human cells could provide relevant information, which
can be missed when using animal cells, in particular
on the mechanisms of NP-mediated interactions and
effects. For example, studies addressing the activation of
toll-like receptors (TLR) by nanomaterials [14,15] should
consider the significant differences in TLR expression,
regulation and function between man and mouse [16].
Many publications describe the direct toxicity of NPs
on human cells in vitro, using a plethora of different
methods that either analyse the number of dead or alive
cells or the metabolic capacity of the cells. These meth-
ods, however, miss to report the many events that can
precede cell death, and overlook the large variety of
effects that can take place without causing cell death.
The immune system is the complex of innate and
adaptive mechanisms responsible for body’s integrity,
which can sense external or internal danger signals and
initiate an appropriate defence response against such
danger. Studying the interaction of NPs with the
immune system is of particular relevance in the case of
NPs used for medical applications, since they are often
injected into the blood stream and come in direct con-
tact with a multitude of immune cells [17]. The innate
immune system provides the first line of defence,
typically triggering a protective inflammatory response
within minutes. If this proves insufficient, the slower
adaptive response is induced. Deranged immune
responses lead to pathology, both in the case of insuffi-
cient activity and in the case of uncontrolled reactions.
Most assays that are currently used to analyse nano-
immunotoxicity were originally designed for the analysis
of the immunotoxicity of dissolved chemicals. In many
instances [8,18] these assays are not suitable for the
purpose of nano-immunotoxicological analysis, and
standard assay protocols applied to chemical toxicity
analysis often cannot be used. New assays have to be
designed for the analysis of nano-immunotoxicity and
nano-immunomodulation.
In this study, metal or metal oxide NPs were used,
many of which are used as core materials in medical
applications. Gold NPs are currently tested for their use
in medicine as drug transporters and for diagnostic ima-
ging, i.e. for cancer detection [19]. Cobalt oxide NPs are
used in a wide range of applications, such as contrast
agents in magnetic resonance imaging [20], and silver
NPs are used as anti-bacterial agents in wound dressings
[21]. The study is specifically directed at identifying the
problems that nano-immunotoxicologists can encounter
when assessing the potential toxic and modulatory
effects of NPs for immune cells in culture, in order to
set up relevant and reliable assays for nano-immunosaf-
ety. To this end, we will focus on human cells that con-
tribute to the innate immune defence mechanisms.
These include professional immune cells, such as mono-
cytes/macrophages, and non-professional defence cells,
such as epithelial cells of the respiratory and gastro-
intestinal tract.
Methods
NP synthesis, characterisation and preparation
Synthesis and characterisation
The inorganic NPs used in this work (Au, Ag, AgO,
CoO, CeO2, Fe3O4) were synthesized by wet chemistry
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methods. All synthesis runs were carried out starting
with organo-metallic and metallic salt precursors either
decomposed or reduced in the presence of stabilisers
using reagents from Sigma-Aldrich, Inc. (St. Louis, MO).
Glass material was sterilised and depyrogenated prior to
use to reduce the levels of lipopolysaccharide (LPS) and
other contaminants in the NP preparations. NP disper-
sions were fully characterised by means of different
techniques: Transmission Electron Microscopy (TEM),
Zeta Potential measurements (Z-Potential), Dynamic
Light Scattering (DLS), X-Ray Diffraction (XRD) and
UV-VIS spectrophotometry. Table 1 reports the charac-
teristics of the NPs synthesized and used in this work.
The 4 nm (mean diameter) Au NPs were synthesized
following the procedure described by Jana et al. [22],
based on the fast injection of 2.64 ml ice-cold freshly
prepared sodium borohydride 0.1 M (NaBH4, reducing
agent) into 200 ml of aqueous solution containing
0.25 mM gold tetrachloroaureate trihydrate (HAuCl4)
and 0.25 mM trisodium citrate (stabilising agent), while
stirring at room temperature. Other sizes of Au NPs
(13 and 20 nm) were obtained with a procedure based
on Turkevich et al. [23], consisting of the fast injection
of a solution HAuCl4 to a boiling solution containing
trisodium citrate under vigorous stirring. Varying the
Au: sodium citrate ratio results in monodispersed Au
NPs with different mean diameters [24]. All uncoated
Au NPs were loosely coated with the negatively charged
citrate ions. Ag NPs synthesis was based on the same
Turkevich’s method. For the 30 nm Ag NPs, 5 ml of
sodium citrate 0.1 M were injected to a boiling solution
of 50 ml of silver nitrate (AgNO3) 1 mM and stirred
vigorously for 5 min. The resulting solution was cooled
down in another vial to avoid deposition of silver on the
glass surface. Oxidation of Ag NPs was negligible during
the time frame of the experiments. Citrate ions were the
coating agent as in the case of Au NPs. Colloidal CoO
NPs were obtained after the synthesis of Co metallic
NPs in organic solvent and further phase transfer. First,
Co NPs of 7 nm mean diameter were prepared follow-
ing the method described by Puntes et al. [25], based on
the thermal decomposition of cobalt carbonyl (Co2(CO)
8) in o-dichlorobenzene in the presence of oleic acid
and trioctylphosphine, under controlled Ar-atmosphere.
Thereafter, 1 mM tetra-methyl ammonium hydroxide
(TMAOH) was used to exchange the NPs surfactant
and thus render the particles water-soluble [26]. Under
these conditions (exposed to air and fluid) the Co NPs
slowly evolve towards cobalt oxide.
The CeO2 particles were synthesized by the noni-
sothermal precipitation procedure based on Zhou et al.
[27] and Chen et al. [28] with some modifications. Briefly,
50 ml of cerium (III) nitrate solution (Ce(NO3)3•6H2O)
0.02 M were set at 70°C with a stirring rate of 500 rpm
followed by the addition of 25 ml TMAOH 1 M. As soon
as the TMAOH was added, the formation of white preci-
pitates was observed. This stage was prolonged for 5 min,
to oxidise the Ce(III)-Ce(IV). Right afterwards, the solu-
tion was rapidly transferred into a water bath, in which
the reaction was continued at 50°C for 20 h. Then,
the resulting solution was centrifuged, washed and resus-
pended in 50 ml TMAOH 1 mM to stabilise the formed
CeO2 NPs.
For Fe3O4 NPs, Massart’s method was followed
[29,30]. Amounts of 1 mmol iron (II) chloride (FeCl2)
and 2 mmol iron (III) chloride (FeCl3) were dissolved in
10 ml deoxygenated water and then added drop wise to
10 ml of a solution of 1 M deoxygenated TMAOH.
Table 1 Characteristics of NPs as synthesized and their solvents
Nanoparticle Composition Mean Diameter (nm) Surface Coating Concentration Solvent
NPs/ml μg/ml nM
Gold (Au) 4 Citrate ions 5 × 1013 56.7 83.1 Na Citrate 0.25 mM; oxidised NaBH4 0.3 mM;
pH 8
Gold (Au) 13 Citrate ions 1012 62.7 1.7 Na Citrate 2.2 mM; pH 7
Gold (Au) 20 Citrate ions 1012 100.0 1.7 Na Citrate 0.85 mM; pH 7
Silver (Ag) 30 Citrate ions 1012 107.8 1.7 Na Citrate 10 mM; pH 7
Silver Oxide (AgO) 10-60 OH ions 1012 107.8 1.7 Oxidized NaBH4 2.64 mM; pH 9
Iron Oxide (Fe3O4) 7 TMAOH 10
14 67.0 166.1 Tetramethylammonium Hydroxide (TMAOH)
5 mM; pH 10
Cobalt Oxide (CoO) 7 TMAOH 1014 38.1 166.1 TMAOH 1 mM; pH 9
Cerium Oxide (CeO2) 7 TMAOH 5 × 10
13 14.0 83.1 TMAOH 1 mM; pH 9
Silver (Ag) 80 Citrate ions 1.1 × 109 3.1 N.D. Na Citrate 20 μM
Gold (Au) 50-100 None N.D. 200 N.D. None
Cerium Oxide (CeO2) 15-30 None N.D. 200 N.D. None
Cobalt Oxide (CoO) 28 None N.D. 200 N.D. None
FexOy 20-50 None N.D. 200 N.D. None
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After 30 min of vigorous stirring under a N2 stream, the
Fe3O4 precipitate was washed by soft magnetic decanta-
tion, re-dissolved in 0.5 M TMAOH and diluted
100 times to obtain the final stable colloidal solution.
For the characterisation of the particles, TEM images
were acquired with a JEOL 1010 Electron Microscope
operating at an accelerating voltage of 80 kV. Samples
for TEM were prepared by drop casting on carbon
coated cooper TEM grids. The grids were left to dry at
room temperature. Observations were made on different
parts of the grid and with different magnifications and
more than 400 particles were computer-analysed and
measured for the size distribution.
Z-Potential measurement (Z-Potential) and Dynamic
Light Scattering (DLS) measurements were made with a
Malvern ZetaSizer Nano ZS Instrument operating at a
light source wavelength of 532 nm and a fixed scattering
angle of 173° for detection. Aliquots of 0.8 ml of the
colloidal NP solutions were placed into the specific cuv-
ette and the software was arranged with the specific
parameters of refractive index and absorption coefficient
of NP material and solvent viscosity (data required to
obtain the correct value for each NP type). Z-Potential
(surface charge) measurements are a commonly used
tool to determine the stability of a colloidal suspension
of electro-statically stabilised NPs. On the other hand,
DLS allows the determination of the hydrodynamic dia-
meter of colloidal particles and conjugates, that is the
diameter of the sphere with the same Brownian motion
as the analysed particle.
X-Ray Diffraction (XRD) spectra were acquired with a
PANalytical X’Pert diffractometer that uses a Cu and Co
Ka radiation source. Samples for XRD consist of the dry
NPs in powder form. For this purpose, destabilisation of
the NPs mixing the colloid with a solvent of different
polarity was followed by soft centrifugation after which
NPs precipitated. The supernatant was discarded, and
the pellet of NPs was dried to eliminate all the moisture.
UV-visible spectrophotometry (UV-VIS) spectra were
acquired with a Shimadzu UV-2400 spectrophotometer.
One ml of the NP solution was placed in a cuvette, and
spectral analysis was performed in the 300 nm to
800 nm range. This technique is widely used for metallic
NPs, such as gold and silver, which exhibit a character-
istic absorbance maximum in the visible range (the Sur-
face Plasmon Resonance, SPR) that changes depending
on the size and surface alterations. However, all the
materials used absorb in the visible or UV range, mak-
ing these measurements appropriate in all cases.
In addition, several NPs were obtained from commer-
cial sources. Ag NPs (80 nm) were obtained from BB
International Ltd. (Cardiff, UK) as colloidal suspension
of 1.1 × 109 NPs/ml (corresponding to 3.1 μg/ml) in
water with 20 μM citrate. Magnetite (iron oxide) NPs
(100 nm) were provided by Chemicell (Berlin, Germany)
as sterile suspension in water with citrate, at the con-
centration of 50 mg/ml (1.8 × 1015 NPs/ml). Several dry
NP powders were purchased from Nanostructured &
Amorphous Materials (NanoAmor), Inc., Houston, TX,
USA. According to the manufacturer’s descriptions, Au
nano-powder consisted of black spherical particles with
diameters ranging from 50-100 nm. The surface area
was 3.3 m2/g and sample purity was stated to be more
than 99.99%. The CeO2 nanopowder was synthesized via
sol-gel processing and consists of spherical, pale yellow
particles with a size range from 15-30 nm, a surface
area of 30-50 m2/g and a density of 7.1 g/cm3; the pur-
ity was 99.9%. Passivated, black and spherical cobalt
oxide (CoO) particles were synthesized via Plasma Che-
mical Vapour Deposition (CVD). These particles had a
diameter of 28 nm, a surface area of 40-60 m2/g, and a
density of 8.9 g/cm3; the purity was 99.8% with small
amounts of Ni (0.08%) and Fe (0.01%). Iron(II, III)oxide
powder (FexOy; NanoAmor) comprised of spherical, red-
dish brown particles with a diameter of 20-50 nm, a sur-
face area of about 50 m2/g, a density of 5.2 g/cm3 and a
purity of more than 98%. The dry particles were resus-
pended in endotoxin-free phosphate buffered saline to
obtain particle suspensions with a final concentration as
indicated for the different experiments. For most experi-
ments, a volume of 10 μl of the NP suspension was
added to 100 μl cell culture medium, resulting in a 9.1%
v/v NP suspension, unless stated otherwise. For all the
NP suspensions obtained by adding solvents to dry
powders, we invariably observed that the particles aggre-
gated and agglomerated, resulting in NP-derived micro-
meter scale materials (data not shown). The list of all
NPs used in this study is reported in Table 1.
Preparation of NP solvents for biocompatibility in culture
conditions
Initial experiments showed that the solvents (NP-free
aqueous solution in which NPs are dispersed) used to
synthesise and stabilise the particles in solution some-
times had a toxic effect on the different human cell
lines used in our studies, even when used at a final con-
centration of 9.1% v/v. In order to avoid the analysis of
chemical toxicity caused by the solvents instead of
nanotoxicity, the cytotoxicity of all solvents in the
absence of NPs was tested prior to the analysis of NP-
induced immuno-toxicity effects. For this purpose, two
sets of solvents were prepared and used as controls in
the biological tests. One set of solvents was identical to
the recipe of synthesis except for the precursor reagents,
while the other was a NP solution from which NPs were
removed by high-speed centrifugation. As discussed
elsewhere [18], the analysis of these two solvents did
not show relevant differences. Only those solvents
that did not show any cytotoxic effect on THP-1 and
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A549 cells, as detected using the commercially available
CellTiterBlue test (Promega, Madison, WI), were used
for further analysis.
Cell lines, primary cells and culture methods
A549 cell line and transfected reporter cell lines
The adherent human lung epithelial cell line A549
(DSMZ, Braunschweig, Germany) was cultured in
RPMI-1640 medium supplemented with L-glutamine
(4 mM), penicillin and streptomycin (each at 100 μg/ml)
and 10% (v/v) heat-inactivated foetal bovine serum
(FBS) (all from PAA Laboratories, Pasching, Austria).
Cells were maintained at 37°C in humid air with 5%
CO2. Stably transfected A549 cell lines were established
and cultured as previously described [31]. In this study,
A549 cell lines containing the IL-6 or the IL-8 promoter
sequence linked to luciferase were used.
BEAS-2B cell line
Adherent human bronchial epithelial BEAS-2B cells
(ATCC, LGC Promochem, Teddington, UK) were ori-
ginally isolated from normal bronchial epithelium and
immortalised in culture with an Ad12SV40 hybrid. The
cells were cultured in T-75 flasks pre-coated with a mix-
ture of 0.01 mg/ml human plasma fibronectin (Invitro-
gen, Paisley, UK), 0.03 mg/ml PureCol™ (Inamed
Biomaterials, Fremont, USA) and 0.01 mg/ml bovine
serum albumin (Sigma-Aldrich) dissolved in complete
growth medium. The latter consisted of bronchial
epithelial cell basal medium (BEBM; Lonza, Basel, Swit-
zerland) supplemented with the BulletKit obtained from
Lonza. Cells were grown in a humidified atmosphere at
37°C and 5% CO2. Before reaching 80% confluence, cells
were sub-cultured using 0.25% (v/v) trypsin/0.53 mM
versene solution (LGC Promochem) containing 5 mg/ml
polyvinyl-pyrrolidone (Sigma-Aldrich).
THP-1 cell line
THP-1 (ATCC) is a human acute monocytic leukaemia
cell line that lacks membrane bound immunoglobulins.
THP-1 cells were cultured in RPMI-1640 medium
supplemented with 2 mM L-glutamine, penicillin and
streptomycin (1 IU/ml each), 10 mM HEPES and 10%
heat-inactivated FBS (all from PAA Laboratories) and
maintained at 37°C in humid atmosphere with 5% CO2.
CaCo-2 cell line
The adherent human gut mucosal epithelial cell line
CaCo-2 (human colon carcinoma, Cell Bank ICLC-IST,
Genoa, Italy) was cultured in DMEM medium supple-
mented with 2 mM L-glutamine, 50 μg/ml gentamicin
(all from GIBCO, Invitrogen), and 10% heat-inactivated
FBS (HyClone, Utah, USA). Cells were maintained at 37°
C in humid air with 5% CO2. Before reaching 80%-90%
confluence, cells were sub-cultured using 0.25% (v/v)
trypsin. Medium was refreshed every 4 days. CaCo-2 cells
represent human enterocytes after spontaneous in vitro
differentiation. Upon reaching confluence, the prolifera-
tion rate gradually slowed until stopping, and cells
formed an organised epithelial layer with the morphologi-
cal and functional characteristics of a differentiated
epithelium [32]. Therefore, cells were differentiated by
maintaining them in culture for 15 days without passage
or manipulation, and used afterwards for experimental
purposes in culture medium with 5% (v/v) heat-inacti-
vated human AB serum (Sigma-Aldrich).
Human primary monocytes
Human CD14+ monocytes were isolated from peripheral
blood mononuclear cells (PBMCs) obtained from buffy
coats of healthy donors (Transfusion Centre, Cisanello
Hospital, Pisa, Italy) by magnetic cell separation using
the MIDIMACS technique according to the manufac-
turer’s instructions (Miltenyi Biotec, Bergisch-Gladbach,
Germany). The monocyte purity (>98%) was assessed by
flow cytometry (FACScan; Becton Dickinson, Ruther-
ford, NJ) and validated by microscope observation of
like-stained slides stained with a modification of the
May-Grünwald-Giemsa staining (Diff Quik; Medion
Diagnostics, Düdingen, Switzerland). Cells were cultured
in RPMI-1640 - Glutamax-I medium (GIBCO, Invitro-
gen) supplemented with 50 μg/ml gentamicin and 5%
heat-inactivated AB human serum at 37°C in humid air
with 5% CO2.
Cell viability, cytotoxicity and cell proliferation assays
Metabolic activity - WST-1 assay
The mitochondrial function of cells exposed to NPs was
analysed using the WST-1 assay (Roche Diagnostics,
Basel, Switzerland). A549 cells were seeded in a 96-well
plate at 1 × 104 cells/well/0.1 ml and incubated overnight.
Ag NPs (80 nm; 3.09 μg/ml) were divided in two frac-
tions. One fraction was centrifuged for 15 min at
10,000 rpm, and the pelleted NPs were resuspended in
cell culture medium. Another fraction was used on cells
directly, without solvent exchange. The solvent recovered
after centrifugation was also used as control. To reach
the final concentrations (ranging from 155 to 927 ng/ml),
the NP suspensions were added to cell culture medium
at a volume of 5-30 μl to reach a final volume of 0.1 ml.
After 24 h of exposure to NPs, the WST assay was per-
formed as described by the distributor. The net absor-
bance change at 450 nm taken from the wells of
untreated cells was taken as 100% cell viability.
Cell proliferation - BrdU assay
The proliferation rate of the cells exposed to NPs was
analysed using the BrdU colorimetric assay kit (Roche
Diagnostics). A549 cells were seeded in 96 well plates at
1 × 104 cells/well/0.1 ml medium followed by overnight
incubation. Cells were exposed to Ag NPs either sus-
pended in water or re-suspended in culture medium at
concentrations ranging from 155 to 927 ng/ml, by
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adding 5-30 μl of NP suspensions to the wells to reach a
final volume of 0.1 ml. After 24 h of exposure, the BrdU
assay was performed according to the manufacturer’s
instructions and analysed at 450 nm. Each experiment
included, as control, cells lysed with 1% Triton X-100.
CellTiter-Blue (CTB) cell viability assay
To determine the effects of nanoparticles on cell viabi-
lity the CTB assay from Promega was used. 100 μl of
cells were plated out in 96-well microtiter plates (Corn-
ing Incorporated, Corning, NY) at a density of 5 ×
103 cells/ml for A549 cells, or 5 × 104 cells/ml for THP-
1 cells. A549 cells were plated out one day in advance
in flat 96-well plates and left overnight to adhere and
obtain their normal morphology. THP-1 cells were pla-
ted out on the same day as the particles were added in
round bottom 96-well plates. Thereafter, 10 μl of the
different NP suspensions at scalar concentrations were
applied to the cells (9.1% v/v, at final mass concentra-
tions of 200, 40, 8 and 1.6 μg/ml). The cells were then
incubated for 48 h at 37°C in 5% CO2. Thereafter, the
CTB-assay was performed according to the manufac-
turer’s protocol and the fluorescence signal of resorufin
was detected at 590 nm using a plate-reader (Tecan,
Salzburg, Austria).
Toxilight cytotoxicity assay
The Toxilight assay (Lonza, Cologne, Germany) is a bio-
luminescence-based cytotoxicity assay that quantitatively
measures the release of adenylate kinase (AK) from
damaged cells. The cells were cultured as described for
the CTB assay. After the incubation period, untreated
cells (no particles) of 3 wells were lysed with 10 μl 10%
Triton-X100 in water (Millipore, Billerica, MA) as a
positive control. After 5 minutes incubation, the plates
were centrifuged for 5 min at 400 × g. Thereafter the
Toxilight assay was performed according to the manu-
facturer’s instructions and luminescence was detected
using a plate reader (Tecan).
Cytotox96 non-radioactive cytotoxicity assay
The Cytotox96 assay from Promega is a colorimetric-
based cytotoxicity assay that quantitatively measures the
release of lactate dehydrogenase (LDH) from damaged
cells. The cells were cultured as described for the CTB
assay. After the incubation period, untreated cells of
3 wells were lysed with 10 μl of 10% Triton-X100 in
water (Millipore) as a positive control. After 5 min incu-
bation the plates were centrifuged for 5 min at 400 × g.
The Cytotox96 assay was then performed as described
by the manufacturer and measured at 490 nm.
Neutral red cell viability assay
For assessment of effects on cell viability, the neutral red
cytotoxicity assay was performed. BEAS-2B cells were
seeded in pre-coated 96-well plates by adding to each
well 200 μl of a cell suspension at 1 × 105 cells/ml, and
the cells were grown to sub-confluence for 48 h. Cells
were then exposed to 200 μl of the NP solutions or the
corresponding solvents at 9.1% (v/v) in complete growth
medium for 24 h. A solution of 1 mM paraquat (PQ) in
culture medium was used as positive control. At the end
of the exposure period the neutral red cytotoxicity assay
was performed based on the INVITTOX protocol
n°64 (ECVAM DB-ALM, http://ecvam-dbalm.jrc.ec.
europa.eu/). The data, analysed at 540 nm, were
expressed as percentage cell viability compared to unex-
posed control cultures (100% viability).
Cell damage and genotoxicity - micronucleus assay
Heparinised blood was obtained from two individual
healthy donors (age <40 years, non-smokers, no medi-
cation for at least 2 weeks before donation) by veni-
puncture in Li-heparin tubes (Monovette®, Sarstedt
AG & Co., Nümbrecht, Germany) according to stan-
dard medical protocol and with formal consent of the
donors. The blood was diluted in RPMI-1640 medium
supplemented with 10% FBS, 1.5% phytohaemaggluti-
nin and 1% penicillin-streptomycin, and incubated for
24 h in culture tubes (Falcon, Becton Dickinson Lab-
ware, Franklin Lakes, NJ). Blood cells were then
exposed to NPs for an additional 48 h, by direct addi-
tion in the culture tubes. Wet NPs were used at dilu-
tions 9.1% v/v, and 10-fold dilutions of the original
synthesis product (see Table 1). Dry NPs were resus-
pended in PBS at 2.0 mg/ml and used in culture at 0.2,
2.0, 20, and 200 μg/ml. For each experiment, a negative
control (cells incubated with medium), a positive con-
trol (Mitomycin C 0.5 μM), and the solvent controls
(cells incubated with medium containing solvent used
for NP synthesis) were included. Cytochalasin B (6 μg/
ml) was added after 44 h of culture (20 h after NP
addition), in order to block cytokinesis and obtain
binucleated cells, fundamental for the MN evaluation.
After 48 h of incubation with NPs (72 h from start),
cells were treated with an hypotonic solution for 3 min
and subsequently prefixed in acid solution (3:5 metha-
nol:acetic acid), washed with methanol and finally fixed
with acid solution (6:1 methanol:acetic acid). The sus-
pension was applied on pre-chilled slides and air-dried.
Staining was performed with a 2% Giemsa solution.
Slides were coded and analysed using an optical micro-
scope (final magnification 400x). To assess the genetic
damage, 2000 binucleated cells for each experimental
point were examined, randomly coded, following the
scoring criteria adopted by the Human Micronucleus
Project [33]. Among these, the number of binucleated
micronucleated (BNMN) leukocytes containing one or
more micronuclei was counted. Moreover, in order to
assess the viability index, 500 cells (mononucleated,
binucleated and polynucleated) were scored to calcu-
late the cytokinesis-block proliferation index (CBPI)
according to Surralles [34].
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Detection of inflammatory cell activation
Cytokine gene expression by human primary monocytes
Human monocytes were seeded in a 6-well plate in 2 ml
medium at the density of 5 × 106 cells/well. NPs were
diluted in solvent and added to culture medium at a
volume of 200 μl to reach a final concentration starting
from 4.55% by volume (higher concentrations could not
be used because of endotoxin contamination). Control
cells were exposed to the corresponding NP solvents at
9.1% v/v (i.e., 200 μl added to 2 ml). Exposure to NPs
was also performed in parallel in the presence of LPS
(endotoxin, 50 EU/ml; from E. coli 055:B5; Sigma-
Aldrich). Controls in all experiments were medium alone
(negative control), and LPS alone (50 EU/ml; positive
control). After different times of exposure to NPs, cells
were collected and analysed for mRNA expression of
cytokine and receptor genes by real-time PCR. Evaluated
genes included the inflammatory cytokines IL-1b, IL-18,
and the IL-18 receptor IL-18Ra. Total RNA was
extracted from 4-5 × 106 human monocytes using the
MicroRNeasy Kit (Qiagen, Hilden, Germany). RNA integ-
rity was evaluated with a Bioanalyzer 2100 (Agilent Tech-
nologies, Waldbronn, Germany). Only RNA samples with
a RIN (RNA Integrity Number) value between 7 and
10 were used (highest quality intact RNA). Retrotran-
scription of 500 ng of total RNA was performed with the
QuantiTect reverse Transcription Kit (Qiagen), according
to manufacturer’s instructions. For quantitative or semi-
quantitative evaluation of expression, the retro-tran-
scribed cDNA was amplified with a RotorGene 3000 real-
time cycler (Corbett Research, Doncaster, Victoria, Aus-
tralia) as follows: one initial step at 50°C for 2 min and
95°C for 15 min was followed by 40 cycles at 95°C for
15 sec, and 56°C for 30 sec, and 72°C for 30 sec. The
reaction mix contained 2.5 μl cDNA, 300 μM of primers,
water and Master Mix (QuantiTech Sybr Green PCR Kit,
Qiagen) in a final volume of 25 μl. The primers for b-
actin (housekeeping gene), IL-1b, IL-18, and IL-18Ra
were designed on the sequences published in GenBank in
two different exons, and synthesised by Eurofins MWG
Synthesis GmbH (Ebersberg, Germany). Expression was
calculated in two ways, with comparable results. Semi-
quantitative evaluation of expression was calculated as:
Efficiency target geneCt target gene/Efficiency reference gen-
eCt reference gene. Where Efficiency is the amplification effi-
ciency, the target gene is the gene under analysis, the
reference gene is b-actin, and Ct is the threshold cycle.
For a more quantitative calculation, a standard DNA
curve was constructed and expression of each target gene
(ng/reaction) was calculated as the ratio with expression
of b-actin (ng/reaction).
Cytokine production by differentiated CaCo-2 cells
Differentiated CaCo-2 cells were seeded in a 6-well plate
at the density of 5 × 105 cells/well in 2 ml medium. NPs
suspended in solvent (see Table 1) were added to
culture medium at a volume of 200 μl (dilution at 9.1%).
Control cells were exposed to the corresponding NP sol-
vents at 9.1% v/v (i.e., 200 μl added to 2 ml). Cultures
were prolonged for 15 days (low dose chronic exposure).
Controls in all experiments were medium alone (nega-
tive control), the inflammatory cytokine IL-1b (10 ng/ml;
positive control), and commercial large Co NPs
(originally dry powder of diameter 50-200 nm, depyroge-
nated and resuspended in endotoxin-free saline, which
however were at least partially aggregated upon depyro-
genation and addition to culture medium).
Cell culture supernatants were cleared of cellular deb-
ris and NPs by high speed centrifugation, and frozen at
-80°C until assayed for cytokine production. The multi-
ple analyses of angiogenesis and inflammatory secreted
factors were performed by the Human Cytokine Anti-
body Array Panel A Kit and the Human Angiogenesis
Antibody Array Kit (R&D Systems; Minneapolis, MN).
The protein production was detected by measuring the
ECL chemiluminescence intensity (Pierce, Rockford, IL)
using a VersaDoc Imaging System (Bio-Rad Laboratories
Inc, UK).
Luciferase assay using stably transfected A549 cell lines
The luciferase assay using different stably transfected
A549 cell lines was performed as previously described
[35]. Briefly, cells were plated in 96-well plates (100 μl/
well) at a density of 5 × 103 per well and left overnight
to adhere and reach their normal morphology. On day
2, the cells were exposed to rhTNF-a (20 ng/ml) or left
untreated. Subsequently, 10 μl of the NP solutions were
added and the cells were incubated for 48 hr. The luci-
ferase assay was performed on cell lysates. Supernatant
was removed from the wells and 50 μl passive lysis buf-
fer (Promega) were added for 10 min according to the
manufacturer’s instructions. Then, 40 μl of the cell
lysates were transferred to non-transparent white
96-well microtiter plates (Corning). Forty μl of luciferine
(the luciferase substrate) were added to the cell lysate
and the luminescence was determined immediately
using a plate reader (Tecan).
Statistical Analysis
Experiments were performed twice or more as indicated
in the figure legends. Mean values ± the standard devia-
tion (SD) were calculated and data sets were compared
using the Student’s t-test. A p value < 0.05 was consid-
ered as statistically significant.
Results
NP physical state in culture media
NPs are readily coated with proteins when placed in cell
culture medium. The evolution of the “protein corona”
(PC) on the surface of some of the NPs used in this
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study has been described [36]. The formation of a PC
will influence the cell responses, since cells initially
interact with the particle surface, before coming in con-
tact with the core material. Experimentally, the phenom-
enon can be observed as a red shift of the plasmon
band, caused by the withdrawal of electron density from
the surface of the particle due to the presence of the
nucleophilic groups. An example is shown in Figure 1
(upper panel), showing the shift of UV-Vis absorption
spectra of Au and Ag NPs upon protein coating.
NPs, as colloidal particles, are systems obtained from a
chemical equilibrium, and exist in a meta-stable phase.
Their final fate is the disintegration or agglomeration
towards more stable phases [37]. Thus, even when the
PC prevents the NPs from aggregation, the particles can
still corrode. We have observed that all the inorganic
NP preparations that were used in this work showed a
release of cations with time (data not shown). Similar
data were published for quantum dots (CdSe) [38] and
carbon nanotubes [39], which corrode and release toxic
Cd ions and less toxic carbon derivatives, respectively.
Another consequence that should not be neglected,
given the importance of size in the nano-bio interaction,
is that corroded particles are much smaller in size com-
pared to the original material. Striking evidence of this
phenomenon is provided by the TEM images of Co
NPs, showing that the morphology of the particles is
severely affected 24 h after their dispersion in water
(Figure 2). Spherical NPs with a homogeneous crystal
contrast are transformed into shapeless NPs with a
broader size distribution and polycrystalline nature.
Together with the morphological transformation, an
increase of Co ions in solution has been observed by
inductively-coupled plasma mass spectrometry (up to
10% of the total NP mass; data not shown). This process
is concomitant with the oxidation of Co towards CoO, a
phenomenon that has been observed for all NPs. From
the TEM images, a dissolution of 13% of the mass can
be estimated for Co NPs incubated for 24 h at room
temperature after phase transfer from just synthesized
in dichlorobenzene to water, and of 11% of the mass for
Au NPs after 48 h in cell culture medium (DMEM +
10% FBS) at 37°C.
NP interference with the optically based assays’ readout
parameters
Many biological experimental readout parameters are
based on transmission, i.e., a detector measures the
quantity of transmitted light at a given wavelength, and
this measure is translated into an optical density. These
systems have been designed for testing transparent mat-
ter, such as diluted cell lysates and cell culture media,
and cannot be applied to optically dense materials such
as NPs without accurate validation. Normally, NPs do
not emit light but they can absorb it, thus resulting in
optically dense samples. Density depends on their chem-
istry (e.g., gold absorbs more light than iron oxide), size
(larger NPs absorb more than small NPs) and
concentration.
The NP density can increase the assay readout, leading
to an over-estimation of the optical parameter. For
example, in the case of a cell viability analysis that uses
formazan, the optical density due to formazan (which is
proportional to the number of living cells) can be signif-
icantly increased by the presence of NPs, giving the false
impression of an improved viability and increased prolif-
eration caused by the NPs [6,7]. In the case of toxic
NPs, the decreased formation of formazan (due to
reduced cell metabolism) could be masked by the NPs’
optical density, providing a false impression of lack of
toxicity. Small NPs (4-15 nm) of Au, Ag, AgO, Fe3O4,
CeO2, and CoO, all absorb at the wavelengths used in
most biological assay readouts: 340, 380, 405, 440, 540/
550 nm (Figure 1, lower panel). In addition, some NPs
can inhibit colour formation, thereby mimicking a cyto-
toxic effect. Indeed, it has been observed that carbon
nanotubes can absorb formazan and protect it from
metabolisation by the cells. The decreased colour forma-
tion, due to the direct effect of nanotubes on the dye
rather than to decreased number of living cells, may
thus lead to the false interpretation of a cytotoxic effect
[40,41]. The best option, when possible, is to remove
NPs before performing the assay (for instance when
testing cell supernatants in ELISA assays). Although it
has previously been shown that some nanomaterials,
such as single walled carbon nanotubes, can indirectly
interfere with such assays by adsorbing antibodies or
cytokines [42,43], we have tested the adsorption of dif-
ferent cytokines on the metal and metaloxide particles
used in this study and never found a reduction in the
cytokine detection signal that could be attributed to
cytokine binding to the particles. However, the appro-
priate controls, including cell free systems, have to be
included to ensure the analysis of true NP-induced
effects. In those cases for which this may not be possible
(e.g., in some viability assays), customised assays using
wavelengths of 700-800 nm should be devised, or alter-
native assays that are not based on optical readouts
should be used (e.g., flow cytometry, visual counting of
dead cells).
Toxicity assays
A major issue in devising nano-immunomodulatory
assays is to make the NP suspensions compatible with
the optimal conditions for cellular survival/growth in
culture. Each type of culture medium and additive
should be evaluated for possible interference with the
endpoint measurements of assays aiming at evaluating
cell death/proliferation/metabolic activity, as it is
Oostingh et al. Particle and Fibre Toxicology 2011, 8:8
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Figure 1 Absorption spectra of NPs. Upper panel: UV-visible spectra of Ag NPs (30 nm; a, red colour) and Au NPs (10 nm; b, green colour)
exposed to cell culture medium (DMEM + 10% FBS) at 37°C. Fainter lines: NPs as synthesized. Darker lines: after 48 h in culture medium at 37°C.
Red shift of the absorbance peak is an indication of protein corona formation. Lower panel: absorption spectra of the NPs used in this work. NP
concentration is 1 × 1012 NPs/ml for Au, Ag and AgO and 1 × 1014 NPs/ml for CeO2, CoO and Fe3O4. At these concentrations, all NPs absorb in
the visible range, where most of the biological tests have their readouts. In this figure: 340 nm is the absorption wavelength of NADH, measured
in the LDH assay; 405 nm is the absorption wavelength of the chromophore p-nitroaniline (pNA) measured in the LAL assay for endotoxin
determination; 440 nm, 490 nm and 540 nm are the readout for WST-1, MTS and MTT respectively.
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routinely done in assays for drug toxicity. However,
additional care is needed in the case of nanotoxicity
assessment, since NPs can significantly interact with
medium components (e.g., with serum proteins), and
this interaction will vary depending on the medium
composition and the NP characteristics.
In order to ensure that the effects found in any of the
immunological tests were due to an immune-response
and not to a loss of cell viability, the effects of NPs on
the cell viability were determined using different com-
mercial assays. The CTB assay is based on the ability of
living cells to convert a redox-dye into a fluorescent
product. The Toxilight assay is a bioluminescence-based
cytotoxicity assay that quantitatively measures the
release of adenylate kinase (AK) from damaged cells.
The Cytotox96 assay is a colorimetric-based cytotoxicity
assay that quantitatively measures the release of lactate
dehydrogenase (LDH) from damaged cells. Using a com-
bination of these three assays has the advantage that cell
viability is determined at different levels, with different
reagents and different readout systems.
No significant cytotoxicity was found for any of the
particles that were prepared in solution (see list in
Table 1) when tested on A549 or THP-1 cells, indepen-
dent of the assay used with a maximum incubation time
of 48 h (data not shown). In addition to the particles
that were synthesized in solution, a range of commer-
cially available dry NPs were tested on different cell
types. All types of dry particles formed aggregates after
resuspension, resulting in larger particles in the μm
range. These particles did affect the cell viability in
some cases. As an example, data of cytotoxicity (LDH
release or AK release) and cell viability (metabolic activ-
ity) of four different NP preparations are shown in the
Figure 3 for the monocytic THP-1 cell line after 48 h
incubation. Analysis of the LDH or AK release in the
cell culture supernatant showed very clear cytotoxic
effects of CoO NPs that were well reproducible and
comparable in both assays (one based on colorimetric
readings at 490 nm, and the other on bioluminescence).
In contrast, the CTB assay was not suitable for this ana-
lysis. The fluorescence measurement showed an artificial
Figure 2 TEM images and size distribution analysis of NPs exposed to different aqueous media. Upper panels: 13 nm Au NPs: A, as
synthesized; B, after 48 h incubation at 37°C with DMEM + 10% FBS. Lower panels: 7 nm CoO NPs: C, as synthesized in dichlorobenzene; D, after
24 h at room temperature after phase transfer to water. Scale bars are 100 nm.
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increase of the cell viability, most likely due to the phy-
sical presence of the particles rather than to real parti-
cle-induced effects. The latter data are therefore
considered to be an artefact and, since the viability of
the cells is an important parameter in evaluating the
extent of the immunomodulatory effects, they could
lead to unreliable conclusions.
The optical interference was also observed in the
Micronucleus (MN) assay used to assess genotoxicity of
NPs on human PBMCs. NPs were added to the PBMCs
either in monodispersed suspension (wet) or in powder
form (dry). Experiments were carried out based on
protocols originally designed to test chemical-induced
genotoxicity, which were adapted to NP testing by con-
sidering some of the problems occurring (e.g., aggrega-
tion and sedimentation) [44]. The use of this protocol
showed that genotoxicity of wet NPs could be reliably
detected and no obvious toxicity or genotoxicity due to
the solvents or to the NP preparations was observed
(Additional file 1, Figure S1). Super-imposable results
were obtained with cells from different donors, under-
lining good assay reproducibility (data not shown).
For dry NPs, significant problems occurred during the
sample preparation, with the formation of aggregates/
agglomerates already occurring upon suspension in cell
culture medium. After centrifugation and cell fixation
for counting micronuclei in binucleated cells, large black
spots were observed adhering to cells that practically
covered them and did not allow micronuclei evaluation.
The problem was not solved by sonication. At visual
inspection, all samples contained large particles, irre-
spective of sonication, and the correlograms obtained by
Dynamic Light Scattering analysis confirmed the high
particle sedimentation of particles (data not shown).
Therefore, strategies other than sonication are required
to prevent NP aggregation/agglomeration.
Immunotoxicity and immunomodulation induced by
chemical or biological contaminants
Toxicity due to contaminants can interfere with the cor-
rect evaluation of the NP-induced effects. This might be
due either to solvents or to endotoxin and other carry-
over molecules. It is important to identify possible assay
interference of contaminating molecules or, even worse,
synergistic interactions between NPs and contaminants.
Solvent immunotoxic and immunomodulatory effects
The chemically synthesized NPs, as used in this study, are
in a solvent that is normally not designed to be biocom-
patible. These solvents are intended to stabilise the parti-
cles in solution and avoid aggregation or agglomeration.
Addition of solvent to the culture medium may induce
direct cytotoxicity, or change the osmolarity and pH of
the medium, thereby causing cell damage, and dilute
nutrients, which decreases metabolic activity. Four
citrate-stabilised monodispersed NP preparations (spheri-
cal Au NPs of diameter 4, 13, and 20 nm; and polydis-
persed Ag NPs of average size 30 nm; Table 1) were
examined for their cytotoxic effect on human BEAS-2B
lung cells using the neutral red assay. The four NP solu-
tions contained different amounts of sodium citrate,
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Figure 3 Suitability of different cell viability assays for nanotoxicity testing. Cytotoxicity of different NPs (suspended from dry powders) on
THP-1 cells was tested after 48 h incubation using the Cytotox-96 assay from Promega (left panel) and the Toxilight assay from Lonza (center
panel). In addition, the CellTiter-Blue assay from Promega was used to determine the cell viability (right panel). Data were normalised to the PBS
control (9.1% v/v PBS) and mean values ± SD are shown. The dotted lines represent the values in control cells with PBS (taken as 0% cytotoxicity
in left and centre panels, and as 100% viability in the right panel). The shaded areas represent the SD above and below the control values. * p <
0.05 vs. untreated control.
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giving final concentrations in the culture medium of
0.02 to 0.9 mM. Among the four NP preparations, only
the one containing 0.9 mM sodium citrate (30 nm Ag
NPs) showed significant toxicity, which overlapped the
effect of the solvent alone, reflecting the effect induced
by their respective solvents rather than the type, size and
concentration of the NPs (data not shown).
Another solvent-induced effect was observed with
80 nm Ag NPs (data not shown) on A549 cells. The dif-
ferent concentrations of NPs, resuspended at 1.1 ×
109 NPs/ml (3.09 μg/ml) in water with 20 μM citrate,
were obtained by adding increasing volumes of the NP
suspension (5-30 μl) to the cells to reach a total volume
of 100 μl (NP suspension + culture medium). Using the
WST-1 assay, the number of metabolically active cells
showed a dose-dependent tendency to decrease when
exposed to the solvent alone, an effect that was not evi-
dent with the NP suspension. Replacing the solvent in
the NP suspension with culture medium did not influ-
ence the lack of effect of NPs on A549 metabolic
activity. Likewise, cell proliferation was apparently unaf-
fected, or even increased by the Ag NPs suspended in
solvent, while the solvent alone showed a tendency to
be toxic at the highest concentration. This discrepancy
between NP and solvent effects may be incorrectly inter-
preted as a protective effect of NPs, counteracting the
toxicity caused by chemicals present in the solvent. As
such, these experiments are an example of the risks of
misinterpretations that could be incurred when over-
looking key details. The toxicity is in this case likely due
to the significant decrease in culture medium osmolarity
caused by the addition of up to 30% v/v water, with
consequent cell swelling and damage, while the “protec-
tive” effect of NPs most likely due to their optical den-
sity artificially masking the toxic effect of solvent. Based
on these experiences, the solvent concentration was
kept constant for all assays, independent of the NP con-
centration, to avoid the analysis of solvent effects
instead of NP-induced effects. Using the different cell
lines and the newly prepared biocompatible solvents, no
significant cytotoxic effects could be detected when
using 9.1% v/v of solvent. The effects of the different
solvents on the immunological activation parameters
were also analysed. All solvents included in this study
(see Table 1) were tested on several different stable
transfected A549 cells containing the sequences of
cytokine promoters or the NF-kB binding sequence
linked to the luciferase reporter gene. When these
A549 reporter cells were incubated with the different
solvents some small but significant effects on the induc-
tion of different cytokine promoters were observed [35].
As an example, the constitutive and TNF-a-dependent
induction of the IL-6 promoter in A549 cells was shown
to be inhibited by 20% for some solvents (Figure 4).
Toxicity tests performed with the same cells and sol-
vents indicated that this effect was not due to a loss in
cell viability. These results indicate that the particle sol-
vents can have immunomodulatory effects, in the
absence of direct cytotoxicity.
Another example of solvent-induced immunomodulat-
ing effects is shown in experiments of chronic exposure
of the human differentiated CaCo-2 gut mucosal cells to
Au, CoO and CeO2 NPs. Cells were chronically exposed
to NPs (6-7 μg/ml for Au 4 nm and CoO NPs, 0.15 μg/
ml for CeO2 NPs, corresponding to a 9.1% dilution) or to
their solvents (9.1% dilution) for 15 days, then superna-
tants were collected, centrifuged to eliminate residual
NPs, and tested for the presence of inflammation-related
soluble factors with semi-quantitative dot-blot-like assays
(Proteome Profiler Antibody Arrays). Of the 84 factors
tested, 40 were significantly produced by CaCo-2 cells or
induced by stimulation with IL-1b, the positive control.
The results for four of these factors are shown in Figure 5.
Stimulation with IL-1b could induce production of three
inflammation-related factors, IL-1b, sICAM-1 and
CXCL1/GROa, and could increase the basal production
of another factor, the chemokine CXCL4/PF4. In the case
of IL-1b and CXCL1 production, chronic exposure to
NPs or to their solvents did not have any effect (Figure 5,
left panels). However, the solvent of Au NPs appeared to
have a significant effect on sICAM-1 production, as
potent as that of IL-1b itself (Figure 5, upper right panel).
In this situation, the high increase of sICAM-1 production
caused by the Au NPs cannot be considered as a true
effect, as it is likely due to the solvent. On the other
hand, the solvent of CoO NPs and CeO2 NPs (the same
solvent for both NPs, see Table 1) had no effect on
sICAM-1 production, thus the increase observed with
CoO NPs (but not with CeO2 NPs) can be considered
as a bona fide effect of the particles. Very different
is the situation with the production of chemokine
CXCL4 (Figure 5, lower right panel), as here the Au NP
solvent is inactive, while the CoO/CeO2 NP solvent is
highly effective. In this case, the increase caused by Au
NPs can be considered true, whereas data obtained with
CoO NPs and CeO2 NPs cannot be interpreted. The con-
clusion is that solvents can have unexpected effects in
modulating cell activation, even when not directly toxic
for cells, and that such effects are different depending on
the biological endpoints measured. Thus, solvents must
always be tested in parallel with NP preparations, even
when they are devoid of direct toxicity.
Finally, it should be kept in mind that even when the
solvents do not affect the viability of the cells and do
not induce/modulate an immune response, there is still
the possibility that the solvent and the NPs act in a
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synergistic manner, inducing in combination a higher or
different effect compared to those found when analysing
the single compounds.
Immunomodulating effects of endotoxin in NP preparations
Identifying the presence of biological contaminants in
the NP preparations is important for the correct inter-
pretation of the nano-immunotoxicological results [8].
Endotoxin contamination is the most common type of
biological contamination in in vitro assays, even when
working under sterile conditions, and can result in
inflammatory responses. Testing for the presence of
endotoxin is a common routine in biological labora-
tories, and many commercial assays are available. How-
ever, these assays should be validated for use with NPs,
since most of them are based on optical readings and
can be affected by the optical density of the NP samples
[45]. Thus, before assessing endotoxin contamination,
the suitability of the endotoxin assay must be checked.
An example is given in Figure 6. Three preparations of
Au NPs of different sizes (see Table 1 for characteris-
tics) were tested for their interference with the optical
detection at 405 nm of para-nitroaniline (pNA), the dye
used as indicator of endotoxin presence in one of the
most common assays (QCL-1000® Endpoint Chromo-
genic LAL assay; Lonza). In this assay, increasing con-
centrations of standard endotoxin are detected as
increased release of pNA, which is measured as OD
increase at 405 nm, with a linear detection range
between 0.1 EU/ml and 1.0 EU/ml (Figure 6, lower left
panel). A concentration of pNA was selected (125 μM)
corresponding to that developed in the LAL assay by
0.6 EU/ml of endotoxin. Au NPs were added to pNA
and their OD405 was measured (Figure 6, upper left
panel). It is evident that 4 nm and 13 nm Au NPs
increase significantly the OD readings of pNA. The NP
solvents were all optically inactive (data not shown).
Thus, addition of 50% 4 nm Au NPs to pNA 125 μM
increases the OD405 to a value that, in the LAL assay,
would correspond to 0.73 EU/ml, as opposed to the
initial 0.6 EU/ml. For Au NPs of 4 or 13 nm, these
could never be used at dilutions less than ten-fold, with-
out causing significant interference in the assay. With
these cautions, by testing several batches of Au NPs
4 nm, it is evident that the presence of endotoxin is
variable (possibly depending on the handling conditions
during synthesis or to contaminated glassware), and in
some cases the NPs or their solvent were heavily con-
taminated (Figure 6, upper right panel). To understand
the risk of data misinterpretation that can be caused by
an endotoxin contamination if going undetected, the
activation of human monocytes by endotoxin is shown
in terms of expression of the inflammatory cytokine
140
120
100
80
60
40
20
0
mediumsolventsolventsolventsolvent
AuNPAuNPCoONPFe3O4NP4nm13nm
IL
Ͳ6
pr
om
ot
er
in
du
ct
io
n(
%
)
* * * * *
Figure 4 Solvent immunotoxicity. Four different particle solvents were tested for their immunomodulation on IL-6 promoter transfected A549
cells, either unstimulated or stimulated with TNF-a (20 ng/ml), after 48 h. For IL-6 promoter induction, the luminescence value of untreated cells
was 220 ± 23 RLU (relative light units), while TNF-a-stimulated cells had a value of 1,485 ± 211 RLU. Data were normalised to allow a direct
comparison between stimulated and unstimulated cells and to enable combining data from multiple experiments. * p < 0.05 vs. untreated
control.
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IL-1b (Figure 6, lower right panel). It is evident that as
little as 0.1 EU/ml of endotoxin can already induce sig-
nificant gene expression, which becomes maximal
between 1 and 50 EU/ml. Thus, as far as human mono-
cytes are concerned, NP preparations can be tested only
at dilutions that contain <0.1 EU/ml. It should be said
that different cell types are differently sensitive to endo-
toxin, for instance human epithelial cells of gut and
lung express very low levels of the endotoxin receptor
TLR4 and are therefore relatively resistant to endotoxin
effects, and thus less sensitive to endotoxin contamina-
tion in NP preparations (data not shown).
Synergy of contaminants with NPs
In addition to masking the effects/lack of effects of NPs,
the presence of contaminants can synergise with NPs
and induce unexpected cellular responses in immune
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Figure 5 Production of inflammation-related soluble factors by CaCo-2 cells. Cells were chronically exposed for 15 days to culture medium
alone or containing IL-1b (10 ng/ml, positive control), Au NPs 4 nm (5.2 μg/ml), CoO NPs (3.5 μg/ml), CeO2 NPs (1.3 μg/ml) (all corresponding to
9.1% v/v), or their solvents. Factors were detected in the cell supernatants by Proteome Profiler Antibody Array and evaluated as arbitrary units
by densitometric analysis. Results for IL-1b, sICAM-1, CXCL1 and CXCL4 are reported in the figure, and presented as mean values ± SD from 2-4
replicate determinations.
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Figure 6 Measuring endotoxin contamination in NP preparations. As preliminary step, evaluation of the interference of Au NPs on the pNA
readings at 405 nm was performed. Different concentrations of Au NPs (4, 13, and 20 nm diameter) could significantly increase the readout at
OD405 of 125 μM pNA (round symbols) (p < 0.05 for all concentrations of NPs 4 nm, for the three highest of NPs 13 nm, and for the highest of
NPs 20 nm) (upper left panel). The selected pNA concentration corresponds to that developed by 0.6 EU of endotoxin in the Endpoint
Chromogenic LAL assay (lower left panel). The increase caused by NPs could therefore be misinterpreted as a significant increase in the
presence of endotoxin. For this reason, endotoxin evaluation was then performed only on NP dilutions that did not cause significant interference
with the pNA readings (typically, ≤ 1 μg/ml for Au NPs 4 nm, ≤ 4 μg/ml for Au NPs 13 nm, and ≤ 12.5 μg/ml for Au NPs 20 nm). Five separate
batches of Au NPs 4 nm and their solvents were tested. For dry NPs, the solvent was endotoxin-free PBS. Batch-to-batch variability in the
endotoxin contamination was evident (upper right panel). The importance of avoiding such contamination is shown by the powerful effect of
minute amounts of endotoxin in activating IL-1b gene expression in human monocytes (lower right) (p < 0.05 for all endotoxin concentrations
vs. control; square symbols).
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cells. Taking again endotoxin as an example, in the
case of human monocytes the type and kinetics of acti-
vation can be different in cells exposed to NPs in the
presence of endotoxin, as compared to either stimulus
alone. The kinetics of expression of two inflammatory
genes, the cytokine IL-18 and its receptor IL-18Ra,
have been evaluated in human primary monocytes
exposed for 4 or 24 h to endotoxin-free AgO NPs
(5 μg/ml, i.e., 4.55% v/v), to endotoxin (50 EU/ml) or
to both agents together (Table 2). Regarding expression
of the IL-18 gene, this is rapidly induced by endotoxin
at 4 h and down-regulated at later times (24 h). AgO
NPs do not have a direct effect, nor can they affect the
extent and kinetics of the endotoxin effect. When
examining expression of another inflammation-related
gene (IL-18Ra), again AgO NPs do not show any direct
induction capacity, while endotoxin can induce gene
expression only at later time points. However, when
monocytes are exposed to particles and endotoxin
together there is low but significant IL-18Ra gene
expression already at 4 h, while the endotoxin-induced
expression at 24 h is significantly reduced by the pre-
sence of particles. Thus, AgO NPs have no inflamma-
tory effect by themselves on human monocytes, but
their presence can modulate some aspects of the
inflammatory defence response of monocytes to endo-
toxin. In real life the co-exposure of our immune sys-
tem to more than one agent concomitantly is the rule,
and the study of synergy/co-stimulation/antagonism is
a highly relevant line of research in the field of nano-
immunotoxicology.
Assays for detecting inflammatory effects: cytokine
production and gene expression
As previously detailed, the presence of NPs (chemical
composition, concentration, size and shape) can cause
interference with the optical readouts of many assays for
cellular functions. To assess the inflammatory effects of
NPs, the production of soluble inflammatory cytokines
and other factors is a well-established endpoint, which is
routinely measured by ELISA. To avoid false positive or
negative results caused by the physical presence of NPs
in the cell supernatants, several actions can be taken.
The first is that of centrifuging the cell supernatants
before ELISA to sediment the NPs, a method that works
well but that is time-consuming and involves a signifi-
cant loss of sample volume. Another option is that of
using molecular biology methods for detecting cell acti-
vation, e.g. measuring expression of inflammatory cyto-
kine genes. Also in this case there might be problems
related to the presence of NPs, such as a decreased effi-
ciency of RNA extraction from NP-exposed cells, or a
lower quality/integrity of extracted RNA. A solution,
which however includes pre-determining which gene we
want to look at, is the use of reporter cell lines in which
a reporter gene (e.g. GFP or luciferase) is under the con-
trol of the promoter of the gene of interest. Luciferase is
detected in the cell lysates using a standard luciferase
assay, while GFP expression can be seen using a fluores-
cence microscope, and the presence of NPs can hardly
interfere with the detection. Hereafter, we describe a
series of problems and propose solutions for assessing
cytokine expression/production in response to NPs.
RNA extraction and integrity
When measuring gene expression in NP-treated cells, a
critical step is to assess the efficiency and quality of the
RNA extraction procedure in the presence of NPs. The
results in Table 3 show the recovery of RNA in samples
of human monocytes exposed for 24 h to different types
of NPs (all endotoxin-free and used at 4.55% v/v, corre-
sponding to 0.7-4.9 μg/ml), a treatment that did not
affect cell viability. It is clear that treatment with Au
NPs 4 nm or with CoO NPs does not influence RNA
recovery, which is practically identical to that achieved
in untreated cells. The same holds true for Ag NPs, Au
NPs (20 nm), and Fe3O4 NPs (tested only in one experi-
ment; data not shown). As expected, RNA was effi-
ciently recovered from cells exposed to the various NP
solvents (Table 3). However, RNA extraction was clearly
hampered in cells treated with CeO2 NPs, from which
Table 2 Synergy between NPs and endotoxin in causing biological effects in human primary monocytes
Gene expression (AU)b
Treatmenta IL-18 IL-18Ra
no NPs AgO NPs no NPs AgO NPs
4 h medium 0.77 ± 0.40 0.98 ± 0.20n.s. 0.49 ± 0.04 0.47 ± 0.13n.s.
endotoxin 3.57 ± 0.80 3.04 ± 0.03n.s. 0.65 ± 0.16 1.78 ± 0.37*
24 h medium 0.92 ± 0.11 0.92 ± 0.25n.s. 0.27 ± 0.12 0.82 ± 0.56n.s.
endotoxin 0.31 ± 0.05 0.17 ± 0.05n.s. 18.56 ± 1.86 10.17 ± 2.01*
a Human monocytes were exposed for 4 and 24 h to culture medium alone or to medium containing 50 EU/ml endotoxin. At the beginning of the incubation,
cells were exposed to endotoxin-free AgO NPs (4.9 μg/ml, corresponding to a dilution at 4.55% v/v). Controls were cells exposed to culture medium alone or to a
4.55% dilution of the solvent (no detectable difference).
b Gene expression was assessed by real-time PCR, using b-actin as housekeeping gene. Data are mean ± SD of replicate experiments.
* p < 0.05 vs. corresponding treatment in the absence of NPs; n.s. not significant vs. corresponding treatment in the absence of NPs.
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only about half of the RNA could be extracted. In cells
exposed to AgO NPs, RNA recovery was highly variable,
from completely normal to significantly impaired, in
four different extractions. Despite the variability in RNA
recovery, however, the integrity of the extracted RNA
was always very high, indicating that the presence of
NPs did not induce any particular damage or fragility to
the nucleic acid (Table 3).
Use of reporter cell lines
The A549 reporter cell lines containing the IL-6, IL-8 or
TNF-a promoter sequence or 3 copies of the NF-B
binding sequence were used to analyse the inflammation-
related effects of NPs. The effect of the wet particles on
these reporter cell lines was low or absent as described in
a previous publication [35]. The reporter cell lines proved
useful in testing the immunotoxic and immunomodula-
tory effects of dry NPs, since aggregation and agglomera-
tion of these particles did not influence the assay (the
analysis is performed on cell lysates, and NPs can be
eliminated by washing cells before lysis and centrifuging
the lysates before analysis). The effects of four different
dry NP preparations (Au, CoO, FexOy and CeO2) on the
IL-8 promoter transfected A549 cell line are shown in
Figure 7. Cells were either unstimulated or exposed to
recombinant human TNF-a. CoO particles were found
to decrease the IL-8 cytokine promoter induction, this
reduction being most likely due to the decreased cell via-
bility found when cells were incubated with CoO parti-
cles (data not shown). The other dry NPs tested did not
affect the cell viability (Au, FexOy and CeO2, data not
shown). Moreover, Au and FexOy particles did not have a
major effect on the cytokine promoter induction. How-
ever, the CeO2 particles did significantly induce the IL-
8 promoter. In unstimulated cells the induction was by
68%, while in cells activated with TNF-a a smaller
increase was observed (31%). This is possibly due to the
fact that TNF-a already induced a near-maximal activa-
tion (35-fold increase in the IL-8 promoter induction),
thus largely masking the effect of the CeO2 NPs.
Discussion
Nano-immunosafety is a key area of investigation for
nanotoxicologists who aim at evaluating risks for the
human health. Not only direct toxicity on immune cells,
but even small alterations in the normal defence func-
tions of our innate/inflammatory or adaptive immune
responses could lead to a higher risk of developing dis-
eases. Thus, simple, robust and representative assays are
urgently required for assessing the possible impact of
NPs on human immune functions. For this reason, the
currently used in vitro assays and experimental tools
need to be accurately optimised and validated, in order
to adapt them for the analysis of NP-induced immune
effects. This is not an obvious task, since both NPs and
biological entities (e.g., human immune cells) are com-
plex systems highly reactive to changes in their environ-
ment. Since the physico-chemical characteristics of their
respective environments are significantly different, modi-
fications of the experimental conditions are necessary in
order to bring the two systems together, and these may
strongly alter the characteristics of the particles and the
cells, a fact that commands for a rigorous validation of
assay conditions.
A number of factors can affect the in vitro assays used
for analysing the effects of NPs on immune cells and
immune responses. A first source of variability, even
before assays are performed, is represented by the great
diversity of NPs used in different laboratories or even in
one laboratory at different times. NPs can be synthe-
sized by different methods, yielding products that can
vary from batch to batch, contain variable amounts of
catalysis residues, be more or less contaminated with
biological contaminants, and with characteristics that
can change due to the conditions and the time the parti-
cles are stored [46] (data not shown). Particle contami-
nation can strongly affect the outcome of in vitro and
in vivo experiments. As an example, toxicity of Diesel
exhaust particles was significantly reduced when all che-
mical and biological contaminants were removed from
their surface [47]. NPs used in the present study were
suspended in different solvents, mainly containing
sodium citrate or TMAOH. In agreement with previous
studies [48], citrate showed a dose-dependent cytotoxic
effect on BEAS-2B human primary lung cells. This kind
of observation highlights the need for accurate studies
addressing the possible confounding effects of chemical
contaminants or solvent components on the assessment
Table 3 RNA recovery and integrity from human
monocytes exposed to NPs
Treatmenta RNA recovery
(% control ± SD)b
RNA integrity
(RIN)c
Medium 100.0 9.6
Au NPs 4 nm 96.3 ± 5.8 9.6
AgO NPs 78.8 ± 7.7 9.5
CoO NPs 97.2 ± 3.8 9.6
CeO2 NPs 56.5 ± 4.9 * 9.8
Solvents (all) 97.3 ± 3.4 9.5
a Human monocytes (3-5 × 106 cells/well) were exposed for 24 h to culture
medium alone or to 0.6-4.9 μg/ml (corresponding to 4.55% v/v) of different
NPs or their solvents.
b RNA recovery in control cells varied between 700 and 1400 ng/106 cells in
seven separate experiments. Recovery in NP-treated cells is calculated as
percent of the recovery in control cells (exposed to culture medium alone)
within each single experiment, and expressed as mean ± SD. Recovery in cells
treated with AgO NPs, tested in four experiments, was highly variable.
c A value of RIN (RNA Integrity Number) between 7 and 10 indicates high
quality intact RNA.
* p < 0.05 vs. medium control.
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of true NP-related immune effects. Another type of con-
tamination, of great importance when studying immu-
nomodulating/immunotoxic effects of NPs, is the
biological contamination. NP suspensions used in this
study were sterile (i.e., devoid of live bacterial contami-
nations), but nevertheless both NPs and their solvents
contained variable levels of endotoxin (LPS, endogenous
pyrogen; a component of the bacterial cell wall). Many
immune cells (either cell lines or primary cells), in parti-
cular monocytes/macrophages, are very sensitive to
endotoxin and can be readily activated by trace amounts
of it. Endotoxin is a very common contaminant of glass-
ware, culture media and additives (e.g., FBS), which
cannot be removed by sterilisation. While cell cultures
are routinely controlled for endotoxin contamination,
and handled exclusively with endotoxin-free equipment
and reagents, NP synthesis is usually performed in che-
mical labs using non-decontaminated glassware and
reagents. The way to effectively remove endotoxin is by
incineration (for example by heating to 250°C for
30 minutes), but this treatment is not suitable for NPs
as it induces irreversible agglomeration. This only leaves
the option open of performing the entire synthesis pro-
cess in endotoxin-free conditions and with the use of
pyrogen-free materials [49]. Endotoxin levels should
therefore be measured for each particle preparation, in
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order to ensure that the effects measured cannot be due
to this highly active contaminant. Endotoxin is not the
only bacterial compound able to induce inflammatory
immune reactions, but its heat stability makes its
presence more likely after sterilisation. The availability
of several commercial assays makes identification of
endotoxin easy, but close care should be taken that the
particles do not interfere with the assays [45]. Moreover,
the presence of significant amounts of endotoxin may
also be an indicator of contamination with bacterial
compounds in general, which may go undetected
because of lack of suitable assays for their identification.
A major technical problem in the adaptation of immu-
noassays to the analysis of NP effects is the direct inter-
ference of NPs with the assay procedures and readouts.
The optical density of NPs and their steric hindrance
can interfere with the normal experimental procedures
(e.g., RNA extraction, any density gradient-dependent
procedure) and, in particular, with the optically-based
assay readouts [50]. As shown in the present study, to
bypass the risk of misinterpretation of results it is
recommended to use multiple assays in parallel and to
include a number of controls (particles only, particles
plus readout dye, analysis at time point zero, etc.), and/
or to test NPs only at dilutions that do not cause
interference.
In testing of NP-induced immune effects, the choice
of the biological assay is also of central importance.
Practical reasons, besides the general task of reducing
animal experimentation, command the choice of in vitro
assays. Given the complexity of immune responses,
assays should be designed in such a way as to represent
selected relevant real life situations. For instance, in the
case of nanomedicines to be administered intravenously,
representative in vitro cellular assays should be based on
human blood leukocytes (such as monocytes), which are
the first cells to come in contact with the injected NPs,
and have biological endpoints representing the early
innate/inflammatory type responses (see examples in
Table 2). Likewise, in the case of ingested or inhaled
material, the response of non-professional defence cells
such as human gut and lung epithelial cells can be con-
sidered as representative of the real life situation (see
for example Figure 5 and 7). Primary cells are the first
choice in such assays, as they reproduce the response of
normal cells of normal individuals. In most cases, the
response of primary cells to stimulation is more sensi-
tive than that of continuous cell lines and, in some
instances, also qualitatively different [35]. Thus, when-
ever possible, primary cells are the best choice for set-
ting up representative assays. This is the case for
instance of human monocytes, which are easily accessi-
ble (peripheral blood) and which show responses to pro-
totypical stimuli that are remarkably reproducible from
donor to donor both qualitatively, quantitatively and
kinetically (DB, data not shown). However, the use of
primary cells is not always feasible (e.g., in the case of
primary lung epithelial cells) and is also hampered by
the limited cellular life span, which requires obtaining
fresh cells (most likely from different donors) for each
assay. This makes standardisation very difficult, because
of the difficulty in getting cells and the risk of donor-to-
donor variability (except in special cases, such as blood
monocytes). As an alternative, the use of cell lines
(transformed or tumour cells with unrestrained prolif-
erative capacity) is technically easier and reproducible,
thus suitable to standardisation and applicable to a first-
line screening of the immunomodulatory effects of NPs.
Of course, an absolute requirement is that the selected
endpoint (e.g., activation of IL-8 expression) is represen-
tative of primary cell activation. In this respect,
particular caution should be used in testing the
anti-proliferative and cytotoxic effects of NPs. Indeed,
transformed and tumour cells have a different cell cycle
regulation and cell survival compared to primary cells,
making them particularly unsuitable for cytotoxicity
assays (apoptosis, necrosis, inhibition of proliferation,
etc.). Ideally, every NP effect identified using cell lines
should be validated on primary cells, unless the assay
has already been validated.
Conclusions
The studies reported here have focussed on in vitro
immunoassays, in particular addressing early inflamma-
tory/innate immune cellular responses, as those carried
out by epithelial cells (barrier and active innate defence
cells) and by monocytes/macrophages (professional
innate/inflammatory defence cells). Information on the
adsorption, distribution, metabolism and excretion
(ADME) of nanomaterials is of main importance in
understanding the potential toxicity and also in moni-
toring the biopharmaceutical effects in nanomedicine
[12,13]. Studies have been performed with a multitude
of different nanomaterials to determine the ADME in
mice or rat models upon inhalation, injection or dermal
application. These studies provide valuable information
on the localisation of the nanomaterials in several differ-
ent tissues, which underlies the distinctive pattern of
effects. However, ADME studies cannot provide mean-
ingful information on the features of interaction
between nanomaterials and defence cells in tissues and
organs, and on the mechanisms of the effects/immune
reactions. In contrast, this information can be provided
by in vitro experiments with isolated cells or single cell
types. The use of single cells allows us to understand
the role of each cell type in the observed immune
responses, and will shed light on the mechanism behind
the effects seen in vivo. Understanding the mechanisms
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is the starting point for a more focussed approach to
optimise the safety of nanomedicines or to reduce the
toxicity of nanomaterial-containing products. In addi-
tion, the in vitro mechanistic studies may serve as a
basis for developing representative assays for assessing
immunomodulatory effects of nanomaterials that corre-
late with the in vivo outcomes. Indeed, the rapid devel-
opment of the nanotechnological industry has resulted
in a huge expansion of the different nanomaterials avail-
able, which vary in chemical composition, shape, size,
and surface coating. Safety testing for all these new
materials with in vivo methods is both economically
unfeasible and ethically unacceptable, as large numbers
of animals would be required. Thus, standardised in
vitro assays with selected cell types may be the best
option as screening tools to identify potentially hazar-
dous materials. At present, a comprehensive picture of
nanomaterial-induced effects cannot be obtained unless
both in vivo and in vitro tools are used.
Additional material
Additional file 1: Genotoxic effects of selected NPs on human
peripheral blood leukocytes. Cells in suspension were treated for 48 h
with NPs or their respective solvents. Genotoxicity was evaluated as the
number of binucleated micronucleated (BNMN) leukocytes every 1000
cells from two separate donors. Positive controls (treated with Mitomycin
C 0.5 μM) contained >100 BNMN cells/1000 cells (not shown).
Representative data reported in the figure refer to cells from one of the
two donors treated with the highest NP/solvent concentration (9.1%).
Final NP concentrations in the assay were the following: Au NPs (13 nm)
5.7 μg/ml; CoO NPs 3.5 μg/ml; Fe3O4 NPs 6.1 μg/ml; CeO2 NPs 1.3 μg/ml;
Ag NPs 9.8 μg/ml.
Acknowledgements
This work was partially supported by the FP6 project DIPNA (SRTP 032131).
Author details
1Department of Molecular Biology, University of Salzburg, 5020 Salzburg,
Austria. 2Institut Català de Nanotecnologia (ICN), 08193 Bellaterra, Spain.
3Laboratory of Innate Immunity and Cytokines, Institute of Biomedical
Technologies, National Research Council (CNR), 56124 Pisa, Italy. 4European
Commission, Joint Research Centre (JRC), Institute for Health and Consumer
Protection, Nanobiosciences Unit, 21027 Ispra, VA, Italy. 5Fraunhofer Institute
for Biomedical Engineering, Department of Biohybrid Systems, 66386 St.
Ingbert, Germany. 6Centre for Advanced R&D on Alternative Methods
(CARDAM), Flemish Institute for Technological Research (VITO NV), 2400 Mol,
Belgium. 7Institució Catalana de Recerca i Estudis Avançats (ICREA),
08010 Barcelona, Spain.
Authors’ contributions
GJO was involved in the experimental design of the CTB, Toxilight, Cytotox-
96 and promoter cell line based assays and was heavily involved in the
preparation and the revision of the manuscript. EC prepared the NPs in
solution, performed a main part of the characterisation and wrote the parts
describing the NP synthesis and characteristics. PI performed the assays with
the CaCo2 cells and was involved in the experiments with the human
monocytes, RC was involved in the optimisation of the genotoxicity assays
and in the preparation of the manuscript, RS performed the CTB, Toxilight,
Cytotox-96 and promoter cell line based assays and was involved in writing
of the manuscript, JP performed the genotoxicity assays and was involved in
writing the manuscript, TP has made substantial contributions to the
conception of the manuscript and performed preliminary experiments, YK
performed the WST assays for the A549 cells and was involved in writing
the manuscript, DO performed the BAES-2B experiments and critically
revised the manuscript, FF performed the assays with the human monocytes
and was involved in the experiments with the CaCo-2 cells, HL performed
the BAES-2B experiments and critically revised the manuscript, DL performed
the assays with the CaCo2 cells and was involved in the experiments with
the human monocytes, FR participated in the coordination of the study and
the design of the experiments, IN participated in the coordination of the
study and the design of the experiments and was involved in writing the
manuscript, HT participated in the coordination of the study and the design
of the experiments and was involved in writing the manuscript, VFP
participated in the coordination of the study and the design of the
experiments and was involved in writing the manuscript, AD participated in
the coordination of the study and the design of the experiments and
critically reviewed the manuscript, DB participated in the coordination of the
study and the design of the experiments and was heavily involved in the
preparation and revision of the manuscript.
All authors read and approved of the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 September 2010 Accepted: 9 February 2011
Published: 9 February 2011
References
1. Boczkowski J, Hoet P: What is new in nanotoxicology? Implications for
public health from a brief review of the 2008 literature. Nanotoxicology
2010, 4:1-14.
2. Boverhof DR, David RM: Nanomaterial characterisation: considerations
and needs for hazard assessment and safety evaluation. Anal Bioanal
Chem 2010, 396:953-961.
3. European Commission, Towards a European Strategy for
Nanotechnology. [http://cordis.europa.eu/nanotechnology/actionplan.htm].
4. European Commission, Nanosciences and Nanotechnologies (N&N): an
action plan for Europe 2005-2009. [http://ec.europa.eu/research/
industrial_technologies/policy_en.html].
5. REACH legislation. [http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?
uri=OJ:L:2010:324:0013:01:EN:HTML].
6. Lewinski N, Colvin V, Drezek R: Cytotoxicity of nanoparticles. Small 2008,
4:26-49.
7. Monteiro-Riviere NA, Inman AO, Zhang LW: Limitations and relative utility
of screening assays to assess engineered nanoparticle toxicity in a
human cell line. Toxicol Appl Pharm 2009, 234:222-235.
8. Dobrovolskaia MA, McNeil SE: Immunological properties of engineered
nanomaterials. Nature Nanotech 2007, 2:469-478.
9. Lemarchand C, Gref R, Passirani C, Garcion E, Petri B, Müller R,
Costantini D, Couvreur P: Influence of polysaccharide coating on the
interactions of nanoparticles with biological systems. Biomaterials 2006,
27:108-118.
10. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE: Preclinical studies to
understand nanoparticle interaction with the immune system and its
potential effects on nanoparticle biodistribution. Mol Pharmaceut 2008,
5:487-495.
11. Fischer HC, Chan WCW: Nanotoxicity: the growing need for in vivo study.
Curr Opin Biotechnol 2007, 18:565-571.
12. Liang XJ, Chen C, Zhao Y, Jia L, Wang PC: Biopharmaceutics and
therapeutic potential of engineered nanomaterials. Curr Drug Metab
2008, 9:697-709.
13. Hagens WI, Oomen AG, De Jong WH, Cassee FR, Sips AJAM: What do we
(need to) know about the kinetic properties of nanoparticles in the
body? Regul Toxicol Pharmacol 2007, 49:217-229.
14. Bastús NG, Sánchez-Tilló E, Pujals S, Farrera C, Kogan MJ, Giralt E, Celeda A,
Lloberas J, Puntes V: Peptides conjungated to gold nanoparticles induce
macrophage activation. Mol Immunol 2009, 46:743-748.
15. Chen HC, Sun B, Tran KK, Shen H: Effects of particle size on toll-like
receptor 9-mediated cytokine profiles. Biomaterials 2011, 32:1731-1737.
16. Rehli M: Of mice and men: species variations of Toll-like receptor
expression. Trends Immunol 2002, 23:375-378.
Oostingh et al. Particle and Fibre Toxicology 2011, 8:8
http://www.particleandfibretoxicology.com/content/8/1/8
Page 20 of 21
17. Zolnik BS, González-Fernández Á, Sadrieh N, Dobrovolskaia MA: Minireview:
Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.
18. Pfaller T, Colognato R, Nelissen I, Favilli F, Casals E, Ooms D, Leppens H,
Ponti J, Stritzinger R, Puntes V, Boraschi D, Duschl A, Oostingh GJ: The
suitability of different cellular in vitro immunotoxicity and genotoxicity
methods for the analysis of nanoparticle-induced events. Nanotoxicology
2010, 4:52-72.
19. Jain PK, El-Sayed IH, El-Sayed MA: Au nanoparticles target cancer. Nano
Today 2007, 2:18-29.
20. Pankhurst QA, Connolly J, Jones SK, Dobson J: Application of magnetic
nanoparticles in biomedicine. J Phys D: Appl Phys 2003, 36:R167-R181.
21. Rai M, Yadav A, Gade A: Silver nanoparticles as a new generation of
antimicrobials. Biotechnol Adv 2009, 27:76-83.
22. Jana NR, Gearheart L, Murphy CJ: Seeding growth for size control of 5-
40 nm diameter gold nanoparticles. Langmuir 2001, 17:6782-6786.
23. Turkevich J, Stevenson PC, Hillier J: A study of the nucleation and growth
processes in the synthesis of colloidal gold. Discuss Faraday Soc 1951,
11:55-75.
24. Frens G: Controlled nucleation for regulation of particle-size in
monodisperse gold suspensions. Nature Physical Science 1973, 241:20-22.
25. Puntes VF, Krishnan KM, Alivisatos AP: Colloidal nanocrystal shape and size
control: The case of cobalt. Science 2001, 291:2115-2117.
26. Euliss LE, Grancharov SG, O’Brien S, Deming TJ, Stucky GD, Murray CB,
Held GA: Cooperative assembly of magnetic nanoparticles and block
copolypeptides in aqueous media. Nano Letters 2003, 3:1489-1493.
27. Zhou XD, Huebner W, Anderson HU: Room-temperature homogeneous
nucleation synthesis and thermal stability of nanometer single crystal
CeO2. Appl Phys Lett 2002, 80:3814-3816.
28. Chen HI, Chang HY: Synthesis and characterization of nanocrystalline
cerium oxide powders by two-stage non-isothermal precipitation. Solid
State Commun 2005, 133:593-598.
29. Jolivet JP, Massart R, Fruchart JM: Synthesis and physicochemical study of
non-surfactant magnetic colloids in an aqueous-medium.
New J Chemistry 1983, 7:325-331.
30. Massart R: Preparation of aqueous magnetic liquids in alkaline and acidic
media. IEEE T Magn 1981, 17:1247-1248.
31. Oostingh GJ, Schmittner M, Ehart AK, Tischler U, Duschl A: A high-
throughput screening method based on stably transformed human cells
was used to determine the immunotoxic effects of fluoranthene and
other PAHs. Toxicol In Vitro 2008, 22:1301-1310.
32. Meunier V, Bourrié M, Berger Y, Fabre G: The human intestinal epithelial
cell line Caco-2; pharmacological and pharmacokinetic applications. Cell
Biol Toxicol 1995, 11:187-94.
33. Bonassi S, Fenech M, Lando C, Lin YP, Ceppi M, Chang WP, Holland N,
Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Jia C, Di
Giorgio M, Ferguson LR, Fucic A, Lima OG, Hrelia P, Krishnaja AP, Lee TK,
Migliore L, Mikhalevich L, Mirkova E, Mosesso P, Müller WU, Odagiri Y,
Scarffi MR, Szabova E, Vorobtsova I, Vral A, Zijno A: Human MicroNucleus
Project: international database comparison for results with the
cytokinesis block micronucleus assay in human lymphocytes: effect of
laboratory protocol, scoring criteria, and host factors on the frequency
of micronuclei. Environ Mol Mutagen 2001, 37:31-45.
34. Surralles J, Xamena N, Creus A, Catalan J, Norppa H, Marcos R: Induction of
micronuclei by five pyrethroid insecticides in whole blood and isolated
human lymphocytes cultures. Mutat Res 1995, 341:169-184.
35. Pfaller T, Puntes V, Casals E, Duschl A, Oostingh GJ: In vitro investigation of
immunomodulatory effects caused by engineered inorganic
nanoparticles - the impact of experimental design and cell choice.
Nanotoxicology 2009, 3:46-59.
36. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V: Time evolution of the
nanoparticle protein corona. ACS Nano 2010, 4:3623-3632.
37. Sperling RA, Casals E, Comenge J, Bastus NG, Puntes VP: Inorganic
engineered nanoparticles and their impact on the Immune Response.
Current Drug Metab 2009, 10:895-904.
38. Kirchner C, Liedl T, Kudera S, Pellegrino T, Javier AM, Gaub HE, Stölzle S,
Fertig N, Parak WJ: Cytotoxicity of colloidal CdSe and CdSe/ZnS
nanoparticles. Nano Letters 2005, 5:331-338.
39. Allen BL, Kichambare PD, Gou P, Vlasova II, Kapralov AA, Konduru N,
Kagan VE, Star A: Biodegradation of single-walled carbon nanotubes
through enzymatic catalysis. Nano Letters 2008, 8:3899-3903.
40. Wörle-Knirsch JM, Pulskamp K, Krug HF: Oops they did it again! Carbon
nanotubes hoax scientists in viability assays. Nano Letters 2006,
6:1261-1268.
41. Patri AK, Dobrovolskaia MA, Stern ST, McNeil SE: Preclinical
characterization of engineered nanoparticles intended for cancer
therapeutics. In Nanotechnology for Cancer Therapy. Edited by: Mansoor A.
New York: Taylor and Francis; 2007:105-138.
42. Casey A, Davoren M, Herzog E, Lyng FM, Byrne HJ, Chambers G: Probing
the interaction of single walled carbon nantubes within cell culture
medium as a precursor to toxicity testing. Carbon 2007, 45:34-40.
43. Monteiro-Riviere NA, Inman AO: Challenges for assessing carbon
nanomaterial toxicity to the skin. Carbon 2006, 44:1070-1078.
44. Colognato R, Bonelli A, Ponti J, Farina M, Bergamaschi E, Sabbioni E,
Migliore L: Comparative genotoxicity of cobalt nanoparticles and ions on
human peripheral leukocytes in vitro. Mutagenesis 2008, 23:377-382.
45. Dobrovolskaia MA, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE:
Ambiguities in applying traditional Limulus Amoebocyte Lysate tests to
quantify endotoxin in nanoparticle formulations. Nanomedicine 2010,
5:555-562.
46. Jones CF, Grainger DW: In vitro assessment of nanomaterial toxicity. Adv
Drug Deliver Rev 2009, 61:438-456.
47. Holder AL, Lucas D, Goth-Goldstein R, Koshland CP: Inflammatory response
of lung cells exposed to whole, filtered, and hydrocarbon denuded
diesel exhaust. Chemosphere 2007, 70:13-19.
48. Uboldi C, Bonacchi D, Lorenzi G, Hermanns MI, Pohl C, Baldi G, Unger RE,
Kirkpatrick CJ: Gold nanoparticles induce cytotoxicity in the alveolar type-
II cell lines A549 and NCIH44I. Part Fibre Toxicol 2009, 6:18.
49. Vallhov H, Qin J, Johansson SM, Ahlborg N, Muhammed MA, Scheynius A,
Gabrielsson S: The importance of an endotoxin-free environment during
the production of nanoparticles used in medical applications. Nanoletters
2006, 6:1682-1686.
50. Casey A, Herzog E, Davoren M, Lyng FM, Byrne HJ, Chambers G:
Spectroscopic analysis confirms the interaction between SWCNT and
various dyes commonly used to assess cytotoxicity. Carbon 2007,
45:1425-1432.
doi:10.1186/1743-8977-8-8
Cite this article as: Oostingh et al.: Problems and challenges in the
development and validation of human cell-based assays to determine
nanoparticle-induced immunomodulatory effects. Particle and Fibre
Toxicology 2011 8:8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Oostingh et al. Particle and Fibre Toxicology 2011, 8:8
http://www.particleandfibretoxicology.com/content/8/1/8
Page 21 of 21
